Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

Leukemia Research

Volumn 38, Issue 10, 2014, Pages 1173-1176

  Breccia, Massimo ^a   Luciano, Luigiana ^y   Latagliata, Roberto ^a   Castagnetti, Fausto ^z   Ferrero, Dario ^b   Cavazzini, Francesco ^c   Trawinska, Malgorzata Monica ^d   Annunziata, Mario ^e   Stagno, Fabio ^f   Tiribelli, Mario ^g   Binotto, Gianni ^h   Crisà, Elena ^b   Musto, Pellegrino ⁱ   Gozzini, Antonella ^j   Cavalli, Laura ^k   Montefusco, Enrico ^l   Iurlo, Alessandra ^m   Russo, Sabina ⁿ   Cedrone, Michele ^o   Rossi, Antonella Russo ^p   Pregno, Patrizia ^q   Endri, Mauro ^r   Spadea, Antonio ^s   Molica, Matteo ^a   Giglio, Gianfranco ^t   Celesti, Francesca ^u   Sorà, Federica ^v   Storti, Sergio ^w   D'Addosio, Ada ^x   Cambrin, Giovanna Rege ^r   Isidori, Alessandro ^aa   Sica, Simona ^v   Abruzzese, Elisabetta ^d   Speccha, Giorgina ^p   Rosti, Gianantonio ^z   Alimena, Giuliana ^a   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d S EUGENIO HOSPITAL   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

^f Ospedale Ferrarotto   (Italy)

^g UNIVERSITY OF UDINE   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^j UNIVERSITY OF FLORENCE   (Italy)

^k UNIVERSITY OF PERUGIA   (Italy)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

ⁿ UNIVERSITY OF MESSINA   (Italy)

^o SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^p UNIVERSITY OF BARI   (Italy)

^q MOLINETTE HOSPITAL   (Italy)

^r Ematologia Università Campus Biomedico   (Italy)

^s REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^t Ospedale Civile di Campobasso   (Italy)

^u BELCOLLE HOSPITAL   (Italy)

^v CATHOLIC UNIVERSITY   (Italy)

^w CATHOLIC UNIVERSITY   (Italy)

^x Ospedale Villa S Pietro   (Italy)

^y UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^z UNIVERSITY OF BOLOGNA   (Italy)

^aa Università di Bologna ^*  (Italy)

more..

Author keywords

Age; Chronic myeloid leukemia; Comorbidities; Overall survival

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGE; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CHARLSON COMORBIDITY INDEX; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FLUID RETENTION; HEMATOLOGIC DISEASE; HIGH RISK POPULATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MUSCLE CRAMP; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PLEURA EFFUSION; RASH; RISK FACTOR; SCORING SYSTEM; SOKAL SCORE; VERY ELDERLY; ANIMAL; CLINICAL PRACTICE; COMORBIDITIES; DISEASE FREE SURVIVAL; STATISTICS; TREATMENT OUTCOME;

AGE; CHRONIC MYELOID LEUKEMIA; COMORBIDITIES; OVERALL SURVIVAL;

AGE FACTORS; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICATION ADHERENCE; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 85006635027     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.06.020     Document Type: Article

References (16)

1. Feinstein A.R. The pre-therapeutic classification of co-morbidity in chronic disease. J Cron Dis 1970, 23:455-468.
2. Birim O., Kappetein A.P., Bogers A.J.J.C. Charlson comorbidity index as a predictor of long-term outcome after surgery for non-small cell lung cancer. Eur J Cardiothorac Surg 2005, 28(5):759-762.
3. Breccia M., Latagliata R., Stagno F., Luciano L., Gozzini A., Castagnetti F., et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica 2011, 96:1457-1461.
4. Baccarani M., Saglio G., Goldman J.M., Hochhaus A., Simonsson B., Appelbaum F., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108(6):1809-1820.
5. Breccia M., Frustaci A.M., Cannella L., Stefanizzi C., Latagliata R., Cartoni C., et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukemia patients. Hematol Oncol 2009, 27(3):148-153.
6. Harrison S.J., Johnson P.R.E., Holyoake T.L. The Scotland Leukemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukemia in 1999 and 2000. Scott Med J 2004, 49:87-90.
7. Berger U., Maywald O., Pfirmann M., et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 2005, 19:984-989.
8. Kantarjian H., Keating M., McCredie K., et al. Old age is a sign of poor prognosis in patients with chronic myelogenous leukemia. Southern Med J 1988, 80:1233-1235.
9. Cortes J., Kantarjian H., O'Brien S., et al. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996, 100:452-455.
10. Hilbe W., Apfelbeck U., Fridrik M., et al. Interferon-alpha for the treatment of elderly patients with chronic myeloid leukemia. Leuk Res 1998, 22:881-886.
11. Berger U., Engelich G., Maywald O., et al. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. Leukemia 2003, 17:1820-1826.
12. Cortes J., Talpaz M., O'Brien S., et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003, 98:1105-1113.
13. Rosti G., Iacobucci I., Bassi S., et al. Impact off age on the outcome off patients with chronic myeloid leukemia in late chronic phase: results off a phase II study off the GIMEMA CML Working Party. Haematologica 2007, 92:101-105.
14. Latagliata R., Breccia M., Carmosino I., et al. Real-life" results of front-line treatment with imatinib in older patients (>65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res 2010, 34:1472-1475.
15. Sanchez-Gujio F.M., Duran S., Galende J., et al. Evaluation of tolerability and efficacy on imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study. Leuk Res 2011, 35:1184-1187.
16. Gugliotta G., Castagnetti F., Palandri F., et al. Frontline imatinib treatment off chronic myeloid leukemia: no impact off age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011, 117:5591-5599.